دورية أكاديمية
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
| العنوان: | Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting |
|---|---|
| المؤلفون: | Jiaxiong Tan, Huo Tan, Yangqiu Li |
| المصدر: | Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-4 (2023) |
| بيانات النشر: | BMC, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Diseases of the blood and blood-forming organs LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | TIM-3, Gal-9, Immunotherapy, Hematological malignancies, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract T cell immunoglobulin domain and mucin domain-3 (TIM-3) is an important immune checkpoint (IC) protein in cancer immunosuppression that is considered a novel target for immunotherapy. Moreover, TIM-3, an immuno-myeloid regulator, is highly expressed on the cells of several solid tumors and myeloid leukemia stem cells (LSCs). TIM-3 blockade was shown to have dual effects for directly inhibiting leukemia cells and restoring T cell activation. We summarize several of the latest reports on the role of TIM-3 in immunotherapy for hematological malignancies from the 2022 ASH Annual Meeting (ASH2022). |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2162-3619 |
| Relation: | https://doaj.org/toc/2162-3619 |
| DOI: | 10.1186/s40164-023-00421-2 |
| URL الوصول: | https://doaj.org/article/7611c9d3520843aead56d15daacae216 |
| رقم الأكسشن: | edsdoj.7611c9d3520843aead56d15daacae216 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 21623619 |
|---|---|
| DOI: | 10.1186/s40164-023-00421-2 |